In the phase 2 DAISY trial (ClinicalTrials.gov identifier: NCT04704661) [56], the authors found that SLX4 loss of function mutation is absorbed in T-DXd-resistant HER2+ BC patients and has a role in the T-DXd resistance mechanism in BC cell lines. Here, ERBB2 is linked to breast cancer.